Study of the possible therapeutic effect of LCZ696 in chemotherapy induced pulmonary fibrosis in rats / (Record no. 169553)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 04947namaa22004331i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OSt |
| 005 - أخر تعامل مع التسجيلة | |
| control field | 20250223033348.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 241218s2023 |||a|||f m||| 000 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloguing agency | EG-GICUC |
| Language of cataloging | eng |
| Transcribing agency | EG-GICUC |
| Modifying agency | EG-GICUC |
| Description conventions | rda |
| 041 0# - LANGUAGE CODE | |
| Language code of text/sound track or separate title | eng |
| Language code of summary or abstract | eng |
| -- | ara |
| 049 ## - Acquisition Source | |
| Acquisition Source | Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 615.1 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) | |
| Classification number | 615.1 |
| Edition number | 21 |
| 097 ## - Degree | |
| Degree | M.Sc |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
| Local Call Number | Cai01.08.09.M.Sc.2023.Ma.S |
| 100 0# - MAIN ENTRY--PERSONAL NAME | |
| Authority record control number or standard number | Mai Abdelhalim Mohamed Abdelhalim, |
| Preparation | preparation. |
| 245 10 - TITLE STATEMENT | |
| Title | Study of the possible therapeutic effect of LCZ696 in chemotherapy induced pulmonary fibrosis in rats / |
| Statement of responsibility, etc. | by Mai Abdelhalim Mohamed Abdelhalim ; the Supervision of Dr. Dalaal Moustafa Abdallah, Dr. Noha Nagah Nassar, Dr. Gehan Sobhy Georgy. |
| 246 15 - VARYING FORM OF TITLE | |
| Title proper/short title | / فى التليف الرئوى الناتج عن العلاج الكيميائى فى الجرذان LCZ696دراسة التأثير العلاجي المحتمل ل |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 2023. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 176 pages : |
| Other physical details | illustrations ; |
| Dimensions | 25 cm. + |
| Accompanying material | CD. |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Source | rda content |
| 337 ## - MEDIA TYPE | |
| Media type term | Unmediated |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | volume |
| Source | rdacarrier |
| 502 ## - DISSERTATION NOTE | |
| Dissertation note | Thesis (M.Sc.)-Cairo University, 2023. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc. note | Bibliography: pages 143-176. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Introduction: Pulmonary fibrosis (PF) is a progressively devastating lung disease with no definitive therapeutic strategy. Several factors may precipitate PF including chemotherapy, environmental agents, and infection (as Coronavirus). Disruption of the lung oxidant/antioxidant status along with increased activation of inflammatory and apoptotic mediators are considered as major findings implicated in PF pathogenesis. This study investigated the prospect therapeutic effect of valsartan alone or combined with sacubitril (LCZ696) in chemotherapy-induced PF. Methods: Rats were randomly allocated into four groups; normal control, methotrexate (MTX)-induced PF (once weekly for 2 consecutive weeks), MTX-induced PF treated with valsartan or LCZ696 administered for 28 days initiated 2 weeks after PF induction. Lung histopathological examinations (H&E and Masson’s trichome) and immunohistochemical determination of α-smooth muscle actin (α-SMA) were performed. Additionally, pro-fibrotic, inflammatory, apoptotic, and oxidative stress biomarkers were assayed in lung tissues. Results: LCZ696 exhibited inhibition of the pro-fibrotic biomarker transforming growth factor-1β (TGF-1β) along with Smad7 increment with marked suppression of caspase-3, interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α) compared to valsartan. Though valsartan showed partial improvement, LCZ696 normalized α-SMA and oxidative/nitroactive stress biomarkers (catalase and nitric oxide). Furthermore, histopathological examination of LCZ696 treated group considerably inhibited inflammation and fibrosis in addition to remarkable reduction of collagen deposition. Conclusion and discussion: Collectively, the combined therapy LCZ696 showed superior effects to single valsartan regimen and may be considered as a promising therapeutic modality for chemotherapy-induced PF. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | تم تصميم الدراسة الحالية بهدف أساسي لتوضيح الإمكانية العلاجية لمثبط مستقبلات الأنجيوتنسين وكابح النيبريليسين الأول في فئته (ساكيوبتريل/فالسارتان) كنظام علاجي مشترك مقارنة بالعلاج الفردي فالسارتان في نموذج تليف الرئة الناجم عن الميثوتريكسيت. الدراسة تهدف إلى تمييز الآليات الجزيئية المعقدة واستقصاء تأثيراتها على الأحداث الرئيسية مثل الإجهاد التأكسدي، والالتهاب، والموت المبرمج، والتليف. علاوةً على ذلك، توسع الاستفسار ليشمل استكشاف مسار<br/> Neprilysin/Natriuretic peptides/ TGF-β1/Smad3<br/> من أجل تحقيق هذه الأهداف، خضعت الدراسة الحالية لتقسيم إلى مرحلتين: المرحلة التجريبية والمرحلة الأساسية. تمت المرحلة التجريبية لتحديد الجرعة الفعّالة المثلى للنظام العلاجي المشترك ساكيوبيتريل/فالسارتان. |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE | |
| Issues CD | Issues also as CD. |
| 546 ## - LANGUAGE NOTE | |
| Text Language | Text in English and abstract in Arabic & English. |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Durgs |
| Source of heading or term | qrmak |
| 653 #0 - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | α-SMA |
| -- | LCZ696 |
| -- | pulmonary fibrosis, |
| -- | TGF-1β |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Dalaal Moustafa Abdallah |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Noha Nagah Nassar |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Gehan Sobhy Georgy |
| Relator term | thesis advisor. |
| 900 ## - Thesis Information | |
| Grant date | 01-01-2023 |
| Supervisory body | Dalaal Moustafa Abdallah |
| -- | Noha Nagah Nassar |
| -- | Gehan Sobhy Georgy |
| Universities | Cairo University |
| Faculties | Faculty of Pharmacy |
| Department | Department of Pharmacology & Toxicology |
| 905 ## - Cataloger and Reviser Names | |
| Cataloger Name | Shimaa |
| Reviser Names | Huda |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Dewey Decimal Classification |
| Koha item type | Thesis |
| Edition | 21 |
| Suppress in OPAC | No |
| Source of classification or shelving scheme | Home library | Current library | Date acquired | Inventory number | Full call number | Barcode | Date last seen | Effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|
| Dewey Decimal Classification | المكتبة المركزبة الجديدة - جامعة القاهرة | قاعة الرسائل الجامعية - الدور الاول | 18.12.2024 | 89534 | Cai01.08.09.M.Sc.2023.Ma.S | 01010110089534000 | 18.12.2024 | 18.12.2024 | Thesis |